Erlotinib Study for Myelodysplastic Syndrome (MDS)

NCT00977548 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndrome

Interventions

DRUG: Erlotinib

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]